6 Top Gainers In Healthcare Sector (RNN, LOGC, TCRR...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Rexahn Pharmaceuticals Inc. (RNN)

Rexahn Pharma is a clinical-stage biopharmaceutical company developing novel, targeted therapeutics for the treatment of cancer.

Gained 25.28% to close Tuesday's (Apr.16) trading at $6.74.

News: The Company has entered into a collaboration with BioSense Global LLC, a New Jersey- and Suzhou, China-based biopharmaceutical company, to advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China.

RX-3117 is Rexahn Pharma's drug candidate that is currently being studied in a Phase 2a clinical trial in combination with Abraxane in first line metastatic pancreatic cancer patients and a Phase 2a clinical trial in patients with advanced or metastatic bladder cancer.

Under the agreement, Rexahn will grant BioSense an exclusive license to develop and commercialize RX-3117 in Greater China. Rexahn will receive an upfront payment and will be eligible to receive additional development, regulatory and commercial milestones up to a total of $226 million contingent on achieving regulatory and commercial goals related to pancreatic cancer and additional indications. Rexahn will also be eligible to receive tiered royalties in the low double digits to mid-teens on annual net sales in the territory.

2. LogicBio Therapeutics Inc. (LOGC)

LogicBio is a genome editing company focused on developing medicines for rare diseases.

Gained 22.69% to close Tuesday's trading at $13.25.

News: No news

Recent events:

-- The Company went public on the Nasdaq Global Market on October 19, 2018, offering its shares at a price of $10 each.

Clinical Trials & Near-term Catalysts:

The Company expects to file an IND for LB-001 in the fourth-quarter of 2019 and initiate a Phase 1/2 trial in methylmalonic academia, an inborn error of metabolism, in 2020.

3. Sesen Bio Inc. (SESN)

Sesen Bio, formerly Eleven Biotherapeutics Inc., is a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer.

Gained 19.46% to close Tuesday's trading at $1.35.

News: No news

Pipeline & Near-term Catalysts:

The Company's lead drug candidate is Vicinium, which is under a phase III trial in patients with high-grade non-muscle invasive bladder cancer, dubbed VISTA.

In January of this year, the Company reported positive preliminary efficacy data for the primary endpoint of its ongoing VISTA Trial - demonstrating clinically meaningful complete response rates in evaluable Carcinoma in situ patients at three, six, nine and 12 months of follow-up in the trial.

New, preliminary analyses from the VISTA trial further demonstrating the activity of Vicinium treatment in patients with high-risk non-muscle invasive bladder cancer were reported last month.

The Company anticipates reporting updated primary and secondary endpoint data from the VISTA trial in mid-2019.

4. IMV Inc. (IMV)

IMV Inc. is a clinical-stage immuno-oncology company developing T cell activating therapies for cancer.

Gained 19.20% to close Tuesday's trading at $3.85.

News: The Company provided a mid-quarter update on the health of its business and upcoming Q2 clinical milestones.

Frederic Ors, Chief Executive Officer said, "From a financial and clinical results standpoint, IMV has recently achieved noteworthy milestones and, based on clinical results observed thus far, our long term outlook remains unchanged and very promising. We have strengthened our balance sheet and expanded our shareholder base through a recent equity offering completed with Wells Fargo as lead underwriter. In addition, IMV has also reported promising clinical results from the phase 2 cohort of the DECIDE clinical study, which we believe confirm the potential activity of DPX-Survivac as monotherapy."

DECIDE study is testing IMV's lead candidate, DPX-Survivac, as a monotherapy in advanced ovarian cancer.

5. scPharmaceuticals Inc. (SCPH)

scPharmaceuticals is a pharmaceutical company whose lead product candidate is Furoscix, a treatment candidate for edema, or fluid overload, in patients with heart failure.

Gained 14.52% to close Tuesday's trading at $2.84.

News: No news

Near-term Catalyst:

The Company anticipates refiling the Furoscix NDA in 2020. Furoscix was turned down by the FDA last June, and the Company was asked to conduct additional human factors studies, device modifications, and potentially a clinical validation study.

6. TCR2 Therapeutics Inc. (TCRR)

TCR2 Therapeutics is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer.

Gained 13.52% to close Tuesday's trading at $18.39.

News: No news

Recent event:

The Company went public on the Nasdaq Global Select Market on February 14, 2019, offering its shares at a price of $15.00 each.

Pipeline & Near-term Catalyst:

The company's lead solid tumor product candidate is TC-210, which recently moved into a phase I/II trial in patients with NSCLC, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Initial data from the trial is expected to be generated in the second half of 2019.

Also in the pipeline are a couple of drug candidates in preclinical testing namely TC-220 for ovarian cancer and TC-110, for CD19-positive B-cell hematological malignancies.